Johnson Financial Group, Inc. Halozyme Therapeutics, Inc. Transaction History
Johnson Financial Group, Inc.
- $2.06 Billion
- Q2 2024
A detailed history of Johnson Financial Group, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 22 shares of HALO stock, worth $1,333. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22Holding current value
$1,333% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
519Shares Held
124MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.07 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$781 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$353 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$245 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$225 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.45B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...